Improve motor and cognitive function
- Trial ID
- NCT07271927
- Official Title
- Evaluation Study of the Effects and Safety of Whole-Body Photobiomodulation Therapy on Motor and Cognitive Changes in Patients With Parkinson's Disease
- Goal
- Improve motor and cognitive function
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Pusan National University Yangsan Hospital
- Study Type
- INTERVENTIONAL
- Enrollment
- 15 participants
- Conditions
- PARKINSON DISEASE (Disorder)
- Interventions
- Photobiomodulation
Plain-Language Summary
The trial wants to find out whether whole-body photobiomodulation can improve movement and thinking problems in people with Parkinson's, while checking that the treatment is safe. Photobiomodulation uses low-level red and near-infrared light applied to the body to stimulate mitochondria, boost cellular energy (ATP), and reduce inflammation and oxidative stress, which may protect neurons and help motor and cognitive function; it is a non-drug therapy meant to be used alongside standard medications like levodopa, not to replace them. Adults aged 40 and up with Parkinson's at Hoehn and Yahr stages 1 to 3 who can walk independently are eligible, while people with very severe cognitive impairment (K-MMSE ≤ 9), implanted electronic devices, a history of seizures or serious psychiatric or medical issues, pregnancy, or recent participation in multiple trials are excluded.
Locations
- Pusan National University Yangsan Hospital, Yangsan, Gyeongsangnam-do, South Korea
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Photobiomodulation. The trial wants to find out whether whole-body photobiomodulation can improve movement and thinking problems in people with Parkinson's, while checking that the treatment is safe. Photobiomodulation uses low-level red and near-infrared light applied to the body to stimulate mitochondria, boost cellular energy (ATP), and reduce inflammation and oxidative stress, which may protect neurons and help motor and cognitive function; it is a non-drug therapy meant to be used alongside standard medications like levodopa, not to replace them. Adults aged 40 and up with Parkinson's at Hoehn and Yahr stages 1 to 3 who can walk independently are eligible, while people with very severe cognitive impairment (K-MMSE ≤ 9), implanted electronic devices, a history of seizures or serious psychiatric or medical issues, pregnancy, or recent participation in multiple trials are excluded.
- Who can participate?
- Participants must be at least 40 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 10 months.